熱門資訊> 正文
Coloplast A/S非GAAP每股收益为3.86丹麦克朗，收入为6.96 B丹麦克朗;重申财年前景
2025-08-19 14:20
- Cambria Global Asset Allocation ETF(GAA) 0
- WisdomTree Earnings 500 Fund(EPS) 0
- Delek US Holdings, Inc.(DK) 0
- Coloplast A/S press release (OTCPK:CLPBF): Q3 Non-GAAP EPS of DKK 3.86.
- Revenue of DKK 6.96B (+1.2% Y/Y).
- Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%.
- EBIT1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.
- FY 2024/25 guidance is unchanged, with organic growth of around 7% and an EBIT margin before special items of 27-28%. • Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. • The assumptions on the reported EBIT margin before special items are largely unchanged. • Special items expectations are unchanged, around DKK 450 million. • Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged.
More on Coloplast A/S
- Coloplast: Despite The Drawdown, Still Not A Buy
- Coloplast: Finally Getting Buyable
- Seeking Alpha’s Quant Rating on Coloplast A/S
- Historical earnings data for Coloplast A/S
- Dividend scorecard for Coloplast A/S
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
